SeaSpine® Announces Full Commercial Launch of NorthStar™ Facet Fusion and Limited Commercial Launch of FLASH™ Navigation Lumbar Facet Fusion
CARLSBAD, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of NorthStar™ Cervical Facet Fusion and the limited commercial launch of FLASH™ Navigation Lumbar Facet Fusion, the latest orthobiologics solutions tailored to specific procedural needs. These first-of-their-kind systems were designed to streamline a reproducible, procedural workflow while maximizing the area for fusion with OsteoStrand® DBM Fibers contained within the facet joint.
NorthStar Facet Fusion is an all-in-one solution that combines OsteoStrand DBM Fiber cervical pellets and disposable facet prep instrumentation, all of which is optimized for use with NorthStar OCT, SeaSpine’s posterior cervical fixation system that entered full commercial launch in October 2021. The dual-purpose instrumentation approximately doubles the surface area within the facet joint when compared to traditional freehand techniques to help facilitate a more robust fusion and significantly improve screw accuracy, as demonstrated in a cadaveric study recently presented at the Cervical Spine Research Society (CSRS).
“NorthStar Facet Fusion is a novel solution to assist with robust facet fusion and safe, reproducible lateral mass screw placement across all settings and experience levels,” stated Erik Olsson, MD, of Southeastern Sports Medicine and Orthopedics at Pardee Hospital in Ashville, NC. “Surgeons from the junior resident to the most experienced surgeon can benefit from utilizing this system for optimizing posterior cervical instrumentation placement and arthrodesis.”
SeaSpine’s FLASH Navigation Lumbar Facet Fusion features instruments that are designed to target and deliver OsteoStrand Plus DBM Fiber pellets within the facet joint during MIS procedures. This limited commercial launch marks the first SeaSpine procedural system developed and integrated with 7D Technology.
“As we continue to build upon our best-of-class orthobiologics portfolio, it is critical for us to provide complementary solutions to our spinal implant and enabling technology portfolios as one continuum of care. These novel procedural solutions for facet fusion will leverage greater access for spinal systems like NorthStar OCT and Mariner, which participate in market opportunities estimated at over $1 billion in the aggregate,” said Frank Vizesi, Vice President, Orthobiologics Research & Development & Clinical Affairs. “These launches are just a great example of how we are focused on improving surgical workflow and resulting patient outcomes with procedure-specific solutions.”
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the design of products and ability to streamline a reproducible, procedural workflow while maximizing the area for fusion; the ability for the Company’s procedural solutions for facet fusion to leverage greater access for spinal systems like NorthStar OCT and Mariner; and whether the full commercial launch of NorthStar™ Cervical Facet Fusion and the limited commercial launch of FLASH™ Navigation Lumbar Facet Fusion represent an example of the Company’s focus on improving surgical workflow and resulting patient outcomes with procedure-specific solutions. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of newly launched products, such as NorthStar™ Cervical Facet Fusion and FLASH™ Navigation Lumbar Facet Fusion, to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of substantial clinical validation of products following limited commercial (or “alpha”) launch; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact